{"id":1215,"date":"2017-04-07T12:00:21","date_gmt":"2017-04-07T12:00:21","guid":{"rendered":"https:\/\/blogs.bmj.com\/spcare\/?p=1215"},"modified":"2017-03-21T12:13:34","modified_gmt":"2017-03-21T12:13:34","slug":"news-and-updates-from-www-palliativedrugs-com-94","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/spcare\/2017\/04\/07\/news-and-updates-from-www-palliativedrugs-com-94\/","title":{"rendered":"News and updates from www.palliativedrugs.com"},"content":{"rendered":"

07\/04\/2017
\n
\nSelected items from the News and Latest Additions sections of www.palliativedrugs.com,<\/a>
\nthe world\u2019s leading palliative care website with over 30,000 members from 169 Countries.<\/strong><\/p>\n

Hot topics<\/strong><\/p>\n

Cochrane review: pharmacological interventions for pruritus in adult palliative care<\/strong>
\n patients<\/strong>
\nIn this update to the original review in 2013, the authors concluded that there were was
\nlow\u2013moderate quality evidence for gabapentin, nalfurafine and cromolyn sodium for itch
\nassociated with chronic kidney disease, and rifampicin and flumecinol for itch associated with
\ncholestasis. Paroxetine may be useful for palliative care patients with itch of various aetiologies,
\nalthough evidence was only available from one study. For more information, click here<\/a>.<\/p>\n

Cochrane review: paracetamol with or without codeine or dihydrocodeine for neuropathic\u00a0<\/strong>pain in adults<\/strong>
\nThe authors concluded that there was insufficient evidence to support or refute the use of
\nparacetamol alone or with codeine or dihydrocodeine for neuropathic pain in adults. For more
\ninformation, click here<\/a>.<\/p>\n

Cochrane review: topical capsaicin (high concentration) for chronic neuropathic pain in<\/strong>
\n adults<\/strong>
\nIn this update to the original review in 2013, the authors concluded that there is moderate quality
\nevidence that high-concentration (8%) capsaicin patches can give moderate pain relief, or better,
\nto a minority of people with post-herpetic neuralgia, and very low quality evidence that it benefits
\nthose with HIV-neuropathy and peripheral diabetic neuropathy. For more information, click here<\/a>.<\/p>\n

Scottish Medicines Consortium: Butec patches for chronic non-malignant pain<\/strong>
\nThe Scottish Medicines Consortium has accepted buprenorphine transdermal patches (Butec \u00ae )
\nwithin NHS Scotland for chronic non-malignant pain of moderate intensity when an opioid is
\nnecessary for adequate analgesia. It is restricted to use in patients >65 years. For more
\ninformation, click here<\/a>.<\/p>\n

NICE evidence summary: oral glycopyrronium bromide for severe sialorrhoea<\/strong>
\nNICE has produced an evidence summary for the use of oral glycopyrronium bromide in children
\nand young people with chronic neurological disorders. For more information, click here<\/a>.<\/p>\n

Drug updates<\/strong>
\nGlycopyrronium oral solution authorized for drooling now available in UK<\/strong>
\nGlycopyrronium 320microgram\/mL oral solution (Sialanar \u00ae ; equivalent to 400microgram\/mL or
\n2mg\/5mL glycopyrronium bromide), authorized for severe drooling in children and adolescents \u22653
\nyears with chronic neurological disease, is now available. The NHS cost for 250mL bottle is \u00a3320.
\nIt is authorized for use via EFT and doses must be reduced in renal impairment. Due to lack of
\ndata the product is not authorized in adults or for long-term use. For the SPC, click here<\/a>.
\nA glycopyrronium bromide 200microgram\/mL (1mg\/5mL; Colonis Pharmaceuticals) oral solution,
\nauthorized for adults for the treatment of peptic ulceration is also available (see our news item
\n30th September 2016<\/a>).<\/p>\n

Glycopyrronium bromide
\nTablets<\/strong> 1mg, 2mg, 28 days@ 1mg t.d.s. = \u00a3602.
\nOral solution<\/strong> 1mg\/5mL, 2mg\/5mL 28 days @ 1mg t.d.s. = \u00a3255 or \u00a3269 respectively.
\nInjection<\/strong> 200microgram\/mL, 1mL or 3mL amp = \u00a31.20.<\/p>\n

Note: other strengths of glycopyrronium bromide oral solution and oral suspension are also
\navailable as unauthorized products via special order 200micorgram\/5mL, 500micorgram\/5mL,
\n2.5mg\/5mL, 5mg\/5mL.<\/p>\n

FDA approves 2mg naloxone nasal spray<\/strong>
\nA 2mg naloxone nasal spray (Narcan \u00ae ; Adapt Pharma) has been approved in the USA for use in
\nopioid-dependent patients, expected to be at risk for severe opioid withdrawal, in situations where
\nthere is a low risk for accidental or intentional opioid exposure by household contacts.
\nA 4mg naloxone nasal spray (Narcan \u00ae ; Adapt Pharma) has been available since February 2016
\n(see our news item 26-11- 2016<\/a>).
\nThe US Product Information for both the 2mg and 4mg naloxone nasal spray can be downloaded
\nfrom here<\/a>. For more information, click here<\/a>.<\/p>\n

Thalidomide updated SPC<\/strong>
\nThe UK SPC for thalidomide Celgene 50mg hard capsules now advises extra care when removing
\ncapsules from the blister to avoid deformation\/breakage and recommends to only press one end of
\nthe capsule to remove from the blister. In addition, it highlights capsules should not be
\nopened\/crushed. If powder makes contact with skin\/mucous membranes, it should be washed or
\nflushed immediately\/with water. For the SPC, click here<\/a>.<\/p>\n

Latest additions
\nWebsite satisfaction survey winners and results<\/strong>
\nResults are available from our satisfaction survey<\/a> (October \u2013 December 2016). Congratulations to
\nthe 5 members randomly selected to receive a free of copy of Introducing Palliative Care 5th
\nedition (IPC5).<\/p>\n

PCF updates<\/strong>
\nThe on-line Palliative Care Formulary is being continually updated. For a full list of all the
\nmonographs updated since the print publication of PCF5, see the Latest additions section of the
\nwebsite or follow us on twitter @palliativedrugs for the latest updates. Over the next few months
\nwe will be working hard in the background on the technical side of the website in preparation for
\nthe publication of PCF6 print edition later this year. Part 2 of PCF (which contains the general
\ntopics) is being reorganised to make it more user-friendly. The new PCF format will be launched
\nfirst on the website in April 2017 and will also contain multiple monographs that have been
\nupdated during the interim period.<\/p>\n

Prepared by Sarah Charlesworth and Andrew Wilcock<\/p>\n","protected":false},"excerpt":{"rendered":"

07\/04\/2017 Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world\u2019s leading palliative care website with over 30,000 members from 169 Countries. Hot topics Cochrane review: pharmacological interventions for pruritus in adult palliative care patients In this update to the original review in 2013, the authors concluded that there were was low\u2013moderate […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":314,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2833],"tags":[],"class_list":["post-1215","post","type-post","status-publish","format-standard","hentry","category-uncategorized","category-updates-from-www-palliativedrugs-com"],"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/users\/314"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/comments?post=1215"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/posts\/1215\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/media?parent=1215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/categories?post=1215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/spcare\/wp-json\/wp\/v2\/tags?post=1215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}